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Prevention of Recurrent Lone Atrial
Fibrillation by the Angiotensin-II Converting
Enzyme Inhibitor Ramipril in Normotensive Patients
Fabio Belluzzi, MD,* Laura Sernesi, MD,* Paola Preti, MD,† Francesco Salinaro, MD,†
Maria Luisa Fonte, MD,† Stefano Perlini, MD, PHD, FESC†
Milan and Pavia, Italy
Objectives The aim of the present study was to verify whether angiotensin-II converting enzyme (ACE) inhibition is also
effective in preventing relapses of lone atrial fibrillation (LAF), that is, in the absence of hypertension and/or
heart disease.
Background Several studies have shown that ACE inhibitors are effective in preventing atrial fibrillation (AF) relapses in pa-
tients with arterial hypertension or several forms of heart disease, that is, in the presence of clinical conditions
that are recognized as causing a higher risk of atrial arrhythmias.
Methods Sixty-two patients admitted to the emergency department of our institution for a first-ever episode of LAF were
enrolled in the study after excluding the presence of cardiac or extracardiac conditions known to be associated
with an increased risk of AF, by medical history, physical examination, complete echocardiographic study, and
the evaluation of blood pressure, thyroid function, urinary catecholamines, serum electrolytes, blood glucose, red
blood cell count, and arterial blood gases. After cardioversion to sinus rhythm by intravenous propafenone, pa-
tients were randomized to either ramipril 5 mg/day (n  31) or placebo (n  31). Holter monitoring and clinical
examination were performed every 3 months.
Results After a 3-year follow-up, AF relapses were observed in 3 patients treated with ramipril and in 10 patients allo-
cated to placebo (p  0.03, Kaplan-Meier, log-rank test). During follow-up, none of the patients developed arte-
rial hypertension or other cardiac or extracardiac condition known to be associated with increased risk of AF,
that is, in all patients the diagnosis of LAF was confirmed.
Conclusions Ramipril is effective in preventing relapses of LAF. (J Am Coll Cardiol 2009;53:24–9) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.071p
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ilthough angiotensin-II converting enzyme (ACE) inhib-
tors and angiotensin-II receptor blockers (ARBs) are not to
e considered antiarrhythmic drugs, several studies have
hown that they are associated with a lower incidence of
entricular arrhythmias in patients with ischemic heart
isease and left ventricular (LV) dysfunction (1–4), possibly
ecause of the adverse effects of angiotensin II on the
ardiac remodeling process. More recently, attention has
een focused in the evaluation of a potential role of these
rugs in the prevention of atrial fibrillation (AF) associated
ith cardiovascular disease (3,5), and previous data from
any different investigators, including our own experience
6), have already shown that these drugs are effective in
rom the *Dipartimento Cardiologico, Unità Coronarica Padiglione Coniugi Sacco,
RCCS Ospedale Maggiore, Policlinico, Milan, Italy; and the †Clinica Medica II,
ondazione IRCCS San Matteo, University of Pavia, Pavia, Italy.c
Manuscript received June 12, 2008; revised manuscript received August 7, 2008,
ccepted August 11, 2008.reventing AF relapses in hypertensive patients (5–9).
hese data have been summarized in a recent meta-analysis
10). However, it must be recognized that in the presence of
cardiac disease-causing atrial overload and/or dysfunction,
he effectiveness of ACE inhibitors and/or ARBs might be
ttributable either to a direct antiarrhythmic effect or to an
ffect on atrial structure and/or function likely able to
avorably modify the arrhythmic substrate, such as the
ncrease in left atrial (LA) dimensions that is frequently
bserved in patients with arterial hypertension and/or LV
ysfunction.
See page 30
In contrast, to the best of our knowledge there are no data
elated to the prevention of AF recurrences with an ACE
nhibitor in the absence of a well-defined cardiac or extra-
ardiac cause, that is, in the setting of lone atrial fibrillation
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December 30, 2008/January 6, 2009:24–9 Ramipril and Lone AFLAF), as defined in 1954 by Evans and Swann (11), an
ffect that has been shown with the ARB irbesartan asso-
iated with amiodarone after electrical cardioversion (12).
The aim of the present study was therefore to investigate
hether the ACE inhibitor ramipril is able to prevent LAF
elapses, that is, to have an antiarrhythmic effect in the
bsence of clinically identifiable atrial structural alterations
nd of cardiac or extracardiac conditions known to be
ssociated with AF.
aterials and Methods
atient selection. The study was aimed at evaluating the
ole of chronic ramipril administration in preventing re-
apses of first-detected persistent LAF. To this aim, all
atients admitted to the Department of Cardiology of our
nstitution from January 2000 to December 2002 for a
rst-ever episode of AF with a duration 12 h (n  469)
nderwent a thorough evaluation (as detailed later) to
xclude cardiac or extracardiac conditions known to be
ssociated with AF. After obtaining informed consent and
ardioversion to sinus rhythm, which was confirmed via
lectrocardiographic (ECG) monitoring for at least 12 h,
ligible patients were discharged and allocated to either
amipril treatment at the dose of 5 mg/day (n  31) or
lacebo (n  31), following an alternated double-blinded
andomization protocol (i.e., successive patients were allo-
ated to ramipril or placebo in an alternating fashion).
On admission, after a 12-lead ECG had confirmed the
iagnosis of AF, a careful history was taken that aimed at
xcluding any clinical evidence of cardiac disease (ischemic,
alvular, or congenital heart disease; dilated, hypertrophic,
r restrictive cardiomyopathy; pericardial disease; intracar-
iac masses; conduction system abnormalities; previous
ardiac surgery) or extracardiac conditions known to be
ssociated with AF, such as arterial hypertension (i.e., blood
ressure 140/90 mm Hg, in agreement with both the
007 European Society of Hypertension/European Society
f Cardiology [ESH/ESC] guidelines [13] and the Seventh
eport of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pres-
ure [JNC-7] [14]), diabetes mellitus, recent surgery, thy-
oid dysfunction, pheochromocytoma, hypokalemia, toxic
buse (alcohol, caffeine, illicit drugs), acute anemia, gastro-
nteric conditions (gallbladder stones, hiatal hernia), cancer,
ever or systemic diseases, pleural disease (effusion, neopla-
ia, inflammation), chronic obstructive lung disease, pneu-
onia, current or previous pulmonary embolism, or intra-
enous fluid overload.
To be included in the study, the patients should be able to
ime the onset of palpitations or of an arrhythmic pulse as
ccurring in the 12 h before hospital admission. Patients in
hom the onset of AF was associated with syncope or
izziness were excluded. An arterial blood pressure 140/90
m Hg in the absence of any antihypertensive medication and
normal standard 2-view plain chest radiograph were also (equired as inclusion criteria. Ve-
ous and arterial blood samples
ere drawn to obtain complete
lood count, gas analysis, serum
lectrolytes, renal function, hepatic
unction, myocardial enzymes, and
hyroid hormones. Only patients
ith normal findings were en-
olled in the study.
A complete echocardiographic
tudy was performed with a 2.5-
o 3.5-MHz probe, and images
ere obtained in parasternal
transverse long axis), apical (4-
nd 2-chamber), and subcostal
iews, excluding patients with a
uboptimal echocardiographic
indow from further analyses.
atients with alterations in regional systolic function (on a
6-segment LV analysis), LV ejection fraction 55% (by
he length-area method in the 4-chamber apical view), LV
hamber dilation (end-diastolic diameter 56 mm), inter-
entricular septum and/or free wall thickness 10 mm,
alvular heart disease, or a mitral regurgitation grade higher
han 0/4 (paraphysiological) were excluded from the study.
he LA was evaluated in telesystole in the 4-chamber apical
iew. Care was taken to measure the longitudinal supero-
nferior diameter (from the mitral valvular plane to the
osterior wall), the mediolateral transverse diameter (from
he interatrial septum to the lateral wall), as well as LA area
y planimetry. Patients with atrial diameters and/or atrial
rea above mean reference value  1 SD were excluded
rom the study. The following reference values were used
mean  SD): superoinferior: 4.3  0.6 cm, mediolateral:
.6  0.4 cm, and LA area: 14.7  2.2 cm2. An additional
xclusion criteria was an abnormal early-to-late peak veloc-
ty ratio (E/A 1) by conventional pulsed Doppler trans-
itral flow velocimetry after conversion to sinus rhythm.
chocardiographic images were evaluated in real time and
oncomitantly recorded on videotape for a further off-line
nalysis, and for comparison with a second ultrasound
valuation at the end of the study.
inus rhythm cardioversion. Pharmacological cardiover-
ion was obtained in all of the enrolled patients within 6 h
ith intravenous propafenone (2 mg/kg in a 10-min bolus
ollowed by 0.007-mg/kg/min infusion). After 12-h ECG
onitoring had confirmed the persistence of a stable sinus
hythm, patients were administered either ramipril 5 mg/
ay or placebo, following the above-described randomiza-
ion procedure (alternated randomization protocol).
ollow-up. All patients were given a questionnaire inves-
igating the presence of palpitations, symptomatic hypoten-
ion, and/or dizziness; regular assumption of the study
rug; and side effects. Patients were re-evaluated every 3
onths for the first year and every 6 months thereafter
Abbreviations
and Acronyms
ACE  angiotensin-II
converting enzyme
AF  atrial fibrillation
ARB  angiotensin-II
receptor blocker
ECG  electrocardiogram/
electrocardiograph
ESH/ESC  European
Society of Hypertension/
European Society of
Cardiology
LA  left atrial/atrium
LAF  lone atrial fibrillation
LV  left ventricularclinical assessment, 12-lead ECG, 24-h Holter monitor-
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Ramipril and Lone AF December 30, 2008/January 6, 2009:24–9ng, and questionnaire collection). Moreover, patients were
rompted to perform a 12-lead ECG should they experi-
nce palpitations. After a 3-year follow-up, an echocardio-
ram was performed by an operator who was blinded to the
atient’s allocation, and a complete blood sample was
ithdrawn for comparison with the baseline results.
tatistics. Data are expressed as mean values  SD. Statis-
ical analyses were performed using the MedCalc software
ackage (version 9.4.2.0, MedCalc Software, Mariakerke,
elgium). Continuous variables were examined for statisti-
al significance by paired or unpaired Student t tests, as
ppropriate. The time to first AF recurrence was analyzed
sing the Kaplan-Meier method and compared using the
og-rank test. A p value of0.05 was considered significant.
esults
ecause of the above mentioned exclusion criteria, of 469
onsecutive patients admitted for a first-ever episode of AF
ith a duration 12 h, LAF was diagnosed in 62 subjects
ho were all randomized to either ramipril or placebo after
iving informed consent. As shown in Table 1, which
ncludes the main demographic features and blood test
esults, no difference was observed between the 2 groups in
aseline data, which according to the study protocol had to
e within the normal range. The same also held true at the
nd of the study, with no significant difference between the
groups, with the exception of an increase in serum
otassium levels in patients allocated to ramipril treatment
Table 1). Regarding the blood pressure values, there was a
onsignificant trend to a minor increase (from 133  6/75 
mm Hg to 134 7/78 6 mm Hg; pNS) in the placebo
roup (Fig. 1). Indeed, according to both the 2007 ESC/ESH
uidelines (13) and the JNC-7 report (14), at the final
ollow-up visit 1 placebo-treated patient was diagnosed as
rade 1 isolated systolic hypertension, his blood pressure values
eing 140/82 mm Hg. In contrast, ramipril treatment was
linical and Ematochemical Parameters at Baselinend at the Final F llow-Up Visit in Ramipril-Treatedatients and in the Control Group
Table 1
Clinical and Ematochemical Parameters at Baseline
and at the Final Follow-Up Visit in Ramipril-Treated
Patients and in the Control Group
Ramipril
Baseline
(n  31)
Placebo
Baseline
(n  31)
Ramipril
Follow-Up
(n  31)
Placebo
Follow-Up
(n  31)
Age (yrs) 60 4 59 7 — —
Women (n) 16 15 — —
Men (n) 13 18 — —
Serum potassium
levels (MEq/l)
4.1 0.5 4.2 0.5 4.5 0.4* 4.3 0.5
Glucose plasma
levels (mg/dl)
93 18 96 15 89 10 90 12
Thyroid-stimulating
hormone (mU/ml)
2.6 0.7 2.7 1.1 2.8 0.9 2.5 1.1
Hemoglobin (g/dl) 15.1 1.4 14.7 1.3 15.6 1.9 15.0 1.6
Urinary
catecholamines
(g/24 h)
67 26 58 36 62 22 61 18p  0.05 follow-up versus respective baseline. Mssociated with blood pressure reduction from 136  4/78 
mm Hg to 128  4/70  4 mm Hg (p  0.05) (Fig. 1).
The echocardiographic data were superimposable both at
aseline and at follow-up, in terms of LV wall motion,
hamber dimensions, wall thicknesses, and systolic and
iastolic function (Table 2). Although remaining in the
ormal range, placebo treatment was associated with an
ncrease in LA diameters and areas. In contrast, no change
n LA anatomy was observed in patients allocated to
amipril treatment.
According to the questionnaires, treatment was very well
olerated (no patient complained of side effects), and it was
aintained by all of the enrolled patients. At the end of the
tudy, AF relapses were observed in 3 ramipril-treated
atients and in 10 control patients (p  0.03) (Fig. 2).
welve of 13 patients experiencing a relapse did come back
o the emergency department, whereas 1 refused the referral
o the hospital after an ECG-proven diagnosis made by her
eneral practitioner at home. Moreover, sporadic episodes
f palpitations were reported by 8 control group patients, 6
f whom had an ECG-proven AF relapse. Spontaneous
ardioversion to sinus rhythm was reported in 3 patients
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Figure 1
Blood Pressure Value at
Baseline and at the Final Follow-Up Visit in
Ramipril-Treated Patients and in the Control Group
*p  0.05 ramipril follow-up versus baseline.
chocardiographic Data at Baseline and at the Finaloll w-Up Visit in Ramipril-Treated P tients and inhe Contr l Group
Table 2
Echocardiographic Data at Baseline and at the Final
Follow-Up Visit in Ramipril-Treated Patients and in
the Control Group
Ramipril
Baseline
(n  31)
Placebo
Baseline
(n  31)
Ramipril
Follow-Up
(n  31)
Placebo
Follow-Up
(n  31)
Left atrium
SI (cm)
4.1 0.3 4.3 0.4 4.0 0.3 4.5 0.4*
Left atrium
ML (cm)
3.4 0.4 3.6 0.3 3.3 0.3 4.2 0.5*†
Left atrium
area (cm2)
14.0 2.1 14.9 2.1 13.2 2.0 16.8 1.9*†
LVEF (%) 66 7 65 7 67 6 63 7
LVEDV (ml) 44 5 47 5 43 5 46 7
Placebo versus respective ramipril. †p  0.05 follow-up versus respective baseline.
LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular ejection fraction;
L  mediolateral atrial diameter; SI  superoinferior atrial diameter.
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December 30, 2008/January 6, 2009:24–9 Ramipril and Lone AFxperiencing an ECG-proven AF episode (1 ramipril-
reated patient and 2 control group patients). In the
amipril-treated patient the AF episode occurred 7 days
fter enrollment, whereas in the other 2 control patients the
F relapse took place at least 2 years after randomization. In
nly 1 patient with a prolonged episode, pharmacological
ardioversion was repeated with propafenone (according to
he above-described protocol). All patients with an AF
elapse continued on the treatment assigned at the begin-
ing of the study.
iscussion
he results of the present study show that ramipril is
ffective in preventing AF relapses in LAF patients, inde-
endent of any sizeable effect on cardiac echocardiographic
natomy when compared with baseline data.
Atrial fibrillation is the most common chronic cardiac
rrhythmia, being a major cause of morbidity and mortality,
ith increased risk for death (15,16), congestive heart
ailure (17), and embolic phenomena, including stroke
15,17). Normally, AF occurs in the presence of structural
eart disease and/or clinical conditions such as hyperten-
ion, diabetes, hyperthyroidism, acute infections, recent
ardiothoracic or abdominal surgery, and systemic inflam-
atory diseases. However, AF may also occur in the absence
f clinical and echocardiographic evidence of cardiovascular,
ulmonary, or endocrine disease, a condition that is cur-
ently defined as LAF, a term that was introduced by Evans
nd Swann (11) in 1953. By the current guidelines’ defini-
ion, the term LAF applies to individuals younger than age
0 years without clinical or echocardiographic evidence of
ardiopulmonary disease, including hypertension (18). Al-
hough LAF is associated with a lower risk of subsequent
vents when compared with other forms of AF, the long-
Ramipril
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Figure 2
Kaplan-Meier Curves Illustrating New-Onset
ECG-Verified AF During the 3-Year Follow-Up in
Ramipril-Treated Patients and in the Control Group
Log-rank test, p  0.03 ramipril versus placebo.
AF  atrial fibrillation; ECG  electrocardiogram.erm prognosis is still debated (19–23). Indeed, any AF dpisode is disturbing for the patient, prompts seeking
edical assistance, carries a sizeable risk of thromboembo-
ism, and increases the possibility of further future episodes.
fter successful sinus rhythm restoration, any decision on
rophylactic antiplatelet or anticoagulant therapy will im-
act not only the subsequent thromboembolic risk but also
he patient’s quality of life, at least in terms of possible
dverse drug reactions, bleeding complications, and collat-
ral effects. The clinical management of any patient expe-
iencing an episode of AF should rely on these consider-
tions, which cannot be overlooked in the setting of LAF,
lthough this clinical condition carries an undoubtedly
enign prognosis.
Although the protocol of the present study did not
nclude a formal quality-of-life assessment, the high number
f hospital readmissions caused by LAF relapses (12 of 13
atients experienced a new documented AF episode) cannot
e overlooked. In this respect, it must be noted that aside
rom preventing new AF episodes, ramipril treatment also
as associated with a marked reduction in emergency
epartment visits (2 vs. 10; p  0.02). During the 3-year
ollow-up, none of the patients was diagnosed as having a
hromboembolic event.
Among the several other aspects that should be taken into
onsideration in the follow-up of patients presenting with
AF, special attention should be given to the possible devel-
pment of arterial hypertension (24) and/or cardiac abnormal-
ties, such as atrial enlargement, that should prompt a change
n the diagnosis. Indeed, in these settings AF cannot be
efined any longer as LAF (18). In the present study, none of
he patients allocated to ramipril treatment developed arterial
ypertension or LA enlargement. In contrast, blood pressure
ended to increase in the placebo group, with 1 patient having
t the last follow-up visit blood pressure values equal to 140/82
m Hg, that is, developing grade 1 (13) (or stage 1 [14])
solated systolic hypertension according to the current guide-
ines’ definitions (13,14). Placebo treatment was also associated
ith an increase in LA chamber dimensions, although remain-
ng within the normal range. Opposite trends were observed in
atients treated with ramipril. In general, these data further
onfirm the diagnosis of LAF in our series, at least over a
-year follow-up, with the exception of a single placebo-treated
atient developing grade 1 (13) (or stage 1 [14]) isolated
ystolic hypertension. To put these data into perspective, it is
mportant to consider that in the setting of LAF, Katritsis et al.
24) showed an increase in LA diameter (from 3.5 0.3 cm to
.8  0.4 cm) over a 3-year follow-up in patients becoming
ypertensive, whereas a 7.5% incidence of hypertension was
eported by Rostagno et al. (25) during a 7-year period.
oreover, Osranek et al. (26) showed that patients with
ncreased LA dimension either at baseline or during follow-up
ave a higher risk of events and of persistent AF. These data
nderscore the relation among AF, blood pressure values, and
A dimensions. Moreover, a collateral clinically relevant aspect
hat cannot be overlooked is the fundamental role of echocar-
iography in the early evaluation of patients presenting a first
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Ramipril and Lone AF December 30, 2008/January 6, 2009:24–9pisode of AF, aimed at clarifying the initial diagnosis and the
ubsequent optimization of the therapeutic strategy.
The present study shows that in patients with blood
ressure in the 130 to 139 mm Hg range, that is, without a
urrent indication to treat with an antihypertensive drug
13), ramipril and placebo had opposite effects on blood
ressure and LA dimensions, the ACE inhibitor being also
ssociated with a lower incidence of LAF relapses. This new
nding could suggest the rationale of considering the
ccurrence of LAF as a marker of subclinical organ damage
n subjects with blood pressure values in the 130 to 139 mm
g range, that is, in the pre-hypertension classification
ccording to the JNC-7 report (14), and of high normal
lood pressure levels according to the 2007 ESC/ESH
uidelines (13).
The association between ramipril treatment and a lower
ncidence of relapses of LAF after the first-documented
pisode in normotensive patients extends previous observa-
ions on the efficacy of ACE inhibition in preventing AF
ncidence in patients with post–acute myocardial infarction
V dysfunction (3), congestive heart failure (27), and
ypertension (28,29). In considering the possible mecha-
ism(s) of these effects, it must be recognized that several
lterations in atrial histological structure have been de-
cribed in LAF patients, such as myocarditis-like alter-
tions, noninflammatory localized cardiomyopathy, and
atchy fibrosis (30,31). Angiotensin II has been shown to
odify the electrical properties of pulmonary vein cardio-
yocytes (32), and it has been shown that ACE inhibition
revents the shortening of the atrial refractory period during
apid atrial pacing that is observed under angiotensin II
xposure (33). Moreover, among the several recent studies
uggesting a possible genetic background contributing to
he etiology of LAF (34–36), a permissive role has been
ttributed to the ACE D allele (37).
Therefore, in line with the observations in other (and
ore common) forms of AF, the protective effect of ACE
nhibition on the electrical and structural remodeling of the
tria is very likely caused by the combination of their actions
n atrial distension/stretch (38), sympathetic tone, local
enin-angiotensin system, a stabilizing effect on electrolyte
oncentration, and last but not least, a minor reduction in
lood pressure, and therefore in cardiac loading conditions
33,39,40). Unfortunately, one limitation of the present
tudy is the lack of data related to the effects of ramipril and
lacebo on time-varying blood pressure values, which are
ndependent predictors of new-onset AF. However, data
rom several studies indicate that AF prevention is also
ependent on the mechanism of blood pressure reduction,
nasmuch as antihypertensive drugs interfering with the
enin-angiotensin system may be more effective (5–10). For
xample, the LIFE (Losartan Intervention For End Point
eduction in Hypertension) study (7) showed that despite
uperimposable blood pressure reduction the angiotensin
eceptor antagonist losartan was more effective than the
eta-blocker atenolol in reducing new-onset AF and inaintaining sinus rhythm in hypertensive patients with
CG LV hypertrophy (7).
onclusions
he present study shows the efficacy of the ACE inhibitor
amipril in preventing relapses of LAF in normotensive
atients. When added to the several previous findings in
ypertensive patients and in patients with LV hypertrophy,
hese data indicate that the antiarrhythmic effect of the
nterference with the renin-angiotensin system is also
resent in the setting of a normal heart in normotensive
atients, that is, in LAF.
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artimento Cardiologico, Unità Coronarica Padiglione Coniugi
acco, IRCCS Ospedale Maggiore, Via Francesco Sforza 35,
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